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Introduction {#acn350826-sec-0005}
============

Vanishing white matter (VWM) is a leukodystrophy, characterized by chronic neurological deterioration and episodes of rapid decline provoked by stresses, especially febrile infections.[1](#acn350826-bib-0001){ref-type="ref"} Neuropathology shows white matter rarefaction and cystic degeneration with feeble astrogliosis, deficient myelin, and immature astrocytes and oligodendrocytes.[2](#acn350826-bib-0002){ref-type="ref"} There is no cure for VWM and patients die prematurely.[1](#acn350826-bib-0001){ref-type="ref"} Recessive mutations in any of the subunits of eukaryotic translation factor 2B (eIF2B), reducing its activity,[3](#acn350826-bib-0003){ref-type="ref"}, [4](#acn350826-bib-0004){ref-type="ref"} cause VWM.[5](#acn350826-bib-0005){ref-type="ref"}, [6](#acn350826-bib-0006){ref-type="ref"}

eIF2B is conditional for the initiation of translation of mRNAs into proteins, regulating protein synthesis rates and orchestrating the integrated stress response (ISR, Fig. [1](#acn350826-fig-0001){ref-type="fig"}A).[7](#acn350826-bib-0007){ref-type="ref"} The ISR is activated by stressors, including oxidative stress, amino acid starvation, infections, and endoplasmic reticulum (ER) stress.[7](#acn350826-bib-0007){ref-type="ref"} Homeostasis of the ER protein‐folding environment is maintained by the unfolded protein response (UPR); the ISR is also one of the three UPR arms (Fig. [1](#acn350826-fig-0001){ref-type="fig"}A). ISR activation leads to phosphorylation of eIF2*α*, which sequesters eIF2B, thereby decreasing general mRNA translation rates and bulk protein synthesis, but increasing translation of specific mRNAs, such as *ATF4*, encoding transcription factor ATF4.[7](#acn350826-bib-0007){ref-type="ref"}

![Polysomal profiling of *2b5^ho^* mouse brain identifies ISR deregulation in mouse VWM and human VWM brain. (A) Summary of ISR‐ and UPR‐regulated transcription included to clarify the link between the ATF4, ATF6‐c, and XBP1s transcription factors and mRNA targets investigated in this study. (B) ATF4‐regulated mRNA levels in gradient fractions from forebrain lysates from 4‐month‐old WT and *2b5^ho^* mice were measured to visualize the mRNA distribution in monosome fraction (A), polysome fractions (B1, less than 5 ribosomes per mRNA; B2, 5 or more ribosomes per mRNA). Graphs show average ± SD, *n* = 3 (*Akt*, qPCR reference). Statistical significance was determined by two‐way ANOVA with Sidak's correction; \**P* \< 0.05, \*\**P* \< 0.01, \*\*\*\**P* \< 0.0001). Raw data for reference mRNAs are shown in Data [S7](#acn350826-sup-0008){ref-type="supplementary-material"}. (C) eIF2*α* phosphorylation, *Gadd34* and *Crep1* mRNA expression levels were measured in cerebellar tissue from WT and VWM mice, as indicated. Graphs show average ± SD, *n* = 3 for eIF2*α* phosphorylation and *n* = 6 for mRNA expression (*Gapdh + Akt*, qPCR reference). Statistical differences in eIF2*α* phosphorylation were determined using a one‐way ANOVA followed by a Dunnet's correction. Differences between WT and *2b5^ho^* qPCR data were assessed with Student's *t*‐test, \**P* \< 0.05, \*\**P* \< 0.01. (D) *DDIT3*, *TRIB3*, *EIF4EBP1* mRNA levels, eIF2*α* phosphorylation, *GADD34* and *CREP1* mRNA levels were quantified in postmortem frontal white matter tissue from VWM patients and controls (negative controls without brain pathology, C1, C2, and disease controls CAR and MS; CAR, CARASAL; MS, multiple sclerosis)**.** Expression differences among VWM patients inversely correlate with postmortem delay time (*AKT + GAPDH*, qPCR reference, *n* = 1). Details on control and patients' tissue are listed in Data [S5](#acn350826-sup-0006){ref-type="supplementary-material"}. Statistical test outcomes are in Data [S6](#acn350826-sup-0007){ref-type="supplementary-material"}.](ACN3-6-1407-g001){#acn350826-fig-0001}

VWM mouse models with homozygous (ho) mutations in eIF2Bδ (Arg484Trp) or eIF2Bε (Arg191His) subunits are representative of the human disease (*2b4^ho^* and *2b5^ho^* mice).[8](#acn350826-bib-0008){ref-type="ref"} Crossbreeding generates *2b4^he^2b5^ho^*, *2b4^ho^2b5^he^*, and *2b4^ho^2b5^ho^* (he, heterozygous) mice. Together they reproduce the clinical spectrum of human VWM with the following order of increasing severity: *2b4^ho^*, *2b5^ho^*, *2b4^he^2b5^ho^*/*2b4^ho^2b5^he^*, and *2b4^ho^2b5^ho^*, as reflected by earlier disease onset, severer motor dysfunction, lower body weight, shorter life span, and severer brain pathology.[8](#acn350826-bib-0008){ref-type="ref"} Using these mice, we previously showed that astrocytes are the primarily affected cell type.[8](#acn350826-bib-0008){ref-type="ref"} In our study, we reveal a constitutive enhanced expression of ATF4‐regulated mRNAs indicative of deregulated ISR homeostasis, strikingly in astrocytes only, both in VWM mice and patients. ISRIB, an ISR inhibitor,[9](#acn350826-bib-0009){ref-type="ref"} ameliorates both ISR deregulation in brain and the clinical disease in VWM mice.

Results {#acn350826-sec-0006}
=======

Increased expression of ATF4‐driven transcriptome in 2b5^ho^ mouse and VWM patient brain {#acn350826-sec-0007}
----------------------------------------------------------------------------------------

We performed polysomal profiling with forebrains of 4‐month‐old WT and *2b5^ho^* mice, shortly before onset of clinical signs in *2b5^ho^* mice, when changes in mRNA translation should be detectable, whereas general changes in mRNA translation in response to tissue damage should be minimal.[8](#acn350826-bib-0008){ref-type="ref"} The polysomal profiles from WT and *2b5^ho^* samples were similar, showing that bulk mRNA translation was not grossly affected by the mutation (Fig. [S1](#acn350826-sup-0001){ref-type="supplementary-material"}). Microarray analysis revealed differential distribution between the monosome and polysome fractions of WT and *2b5^ho^* samples for 33 mRNAs (Data [S2](#acn350826-sup-0003){ref-type="supplementary-material"}), suggesting altered translation rates in *2b5^ho^* brain; the majority was shifted toward the polysome fraction in *2b5^ho^* brain indicating increased translation efficiencies. Strikingly, 17 of the 33 differentially translated mRNAs are regulated by ATF4 (Fig. [1](#acn350826-fig-0001){ref-type="fig"}A),[10](#acn350826-bib-0010){ref-type="ref"} indicating increased ATF4 expression and ATF4‐regulated transcription in *2b5^ho^* forebrain.

We verified the microarray findings for several candidates with qPCR (Fig. [1](#acn350826-fig-0001){ref-type="fig"}B). Most mRNAs with altered translation rates were increased in monosome and polysome fractions from *2b5^ho^* mouse brains, indicating that these mRNAs were regulated at transcript level. We focused on differences in mRNA levels within the polysome fractions, without taking into account their distribution between monosome and polysome fractions. We identified 176 mRNAs with altered level of polysome association in *2b5^ho^* compared to WT forebrain (115 up and 61 down, Data [S3](#acn350826-sup-0004){ref-type="supplementary-material"}), indicating altered synthesis of the encoded proteins. Overrepresentation analysis (Fig. [2](#acn350826-fig-0002){ref-type="fig"}A) highlighted changes in amino acid transport, serine biosynthesis and glycine metabolism. Of these 176 mRNAs 52 are regulated by ATF4,[10](#acn350826-bib-0010){ref-type="ref"} including *Ddit3,* which encodes transcription factor CHOP. ATF4‐regulated mRNAs were enriched fivefold compared to the mRNAs with similar polysome association in WT and *2b5^ho^* forebrain (*P* \< 0.001; Data [S4](#acn350826-sup-0005){ref-type="supplementary-material"}). We verified findings from mice in humans (Fig. [1](#acn350826-fig-0001){ref-type="fig"}D); the expression of ATF4‐regulated mRNAs (*DDIT3*, *TRIB3,* and *EIF4EBP1*) was increased in VWM patients' brain. Microarray analyses of total RNA from white matter confirmed a twofold enrichment of ATF4‐regulated mRNAs in differentially expressed mRNAs in VWM patients compared to controls (*P* \< 0.0001; Data [S4](#acn350826-sup-0005){ref-type="supplementary-material"}).

![Follow‐up analyses show affected cellular functions and ISR deregulation correlating with disease development. (A) Overrepresentation analysis of regulated polysome‐associated mRNAs in *2b5^ho^* mouse forebrain against the gene ontology (GO) database. \# changed, number of mRNAs in GO term differentially associated with *2b5^ho^* polysomes; \# measured, number of mRNAs in GO term detected in WT and *2b5^ho^* polysomes; \# in ontology, total gene number in GO term; results with a *Z* score \>2 and FDR of \<0.15 were considered significant; fold change, average of differentially expressed genes within the dataset for the particular GO term. (B) Expression of the ATF4‐regulated transcriptome in VWM mouse brain correlates positively with disease development. mRNA levels were determined at indicated ages (left hand side) or in indicated genotypes (right hand side). Sagittally sliced brain halves of WT and *2b5^ho^* mice were analyzed at indicated ages (*Gapdh,* qPCR reference; P, postnatal day; HEP, humane end point, as defined by weight loss of more than 15% of body weight for 2 consecutive days and severe ataxia; 7--8 months of age). Graphs show average ± SD, *n* = 2. Statistical analysis on the differences at groups of different ages was done for each mRNA using a two‐way ANOVA (genotype\*day interaction all days) followed by 2 two‐way ANOVAs for each mRNA (one comparing data of \<P21 with ≥P21 and one comparing data of \<P28 with ≥P28 for genotype\*day interaction) using SPSS. Cerebella of indicated mouse genotypes were analyzed at 4‐month‐old age (*Gapdh* + *Akt,* qPCR reference). Graphs show average ± SD, *n* = 3 (*n* = 4 for *2b4^ho^*). Statistical differences were determined using a one‐way ANOVA followed by Tukey's correction. \*\**P* \< 0.01, \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001 (Data [S6](#acn350826-sup-0007){ref-type="supplementary-material"}).](ACN3-6-1407-g002){#acn350826-fig-0002}

Expression of the ATF4 transcriptome is accompanied by reduced eIF2α phosphorylation {#acn350826-sec-0008}
------------------------------------------------------------------------------------

ATF4 transcriptome expression could be enhanced in VWM brain due to ISR activation via eIF2*α* phosphorylation. However, we found that eIF2*α* phosphorylation in brain was significantly reduced in VWM compared to WT mice (Figs. [S1](#acn350826-sup-0001){ref-type="supplementary-material"}C and [S2](#acn350826-sup-0001){ref-type="supplementary-material"}). Dephosphorylation of eIF2*α* is mediated by protein phosphatase 1, using CREP1 or GADD34 as co‐factor.[11](#acn350826-bib-0011){ref-type="ref"} GADD34 is essential for the negative feedback of the ISR (Fig. [1](#acn350826-fig-0001){ref-type="fig"}A), whereas CREP1 functions as a cofactor also in unstressed cells.[12](#acn350826-bib-0012){ref-type="ref"} *Gadd34* but not *Crep1* mRNA expression was increased in *2b5^ho^* brain compared to WT brain (Fig. [1](#acn350826-fig-0001){ref-type="fig"}C), in line with its regulation by ATF4 (Fig. [1](#acn350826-fig-0001){ref-type="fig"}A).[13](#acn350826-bib-0013){ref-type="ref"} In VWM patients' white matter eIF2*α* phosphorylation was significantly decreased compared to controls' (Fig. [1](#acn350826-fig-0001){ref-type="fig"}D) and *GADD34* but not *CREP1* mRNA levels were increased. The decreased level of eIF2*α* phosphorylation can be explained by increased expression of GADD34, resulting from increased *Gadd34* mRNA. Western blot analysis for GADD34 protein was unsuccessful.

Activation of all three UPR branches in patients' white matter was previously reported.[14](#acn350826-bib-0014){ref-type="ref"} We investigated activation of the branches regulated by ATF6 or IRE1*α* in *2b5^ho^* mouse brain. We measured specific markers for ATF6‐driven transcription (*Pdia4* mRNA) and IRE1*α* activation (*Xbp1* mRNA splicing).[15](#acn350826-bib-0015){ref-type="ref"}, [16](#acn350826-bib-0016){ref-type="ref"} qPCR analyses did not show increased expression of these markers, arguing against recent or ongoing activation of these UPR branches in *2b5^ho^* brain (Fig. [S3](#acn350826-sup-0001){ref-type="supplementary-material"}). The previously reported expression of UPR markers in patient brains was determined in end‐stage disease.[14](#acn350826-bib-0014){ref-type="ref"} We therefore measured *Pdia4* mRNA expression and *Xbp1* mRNA splicing in *2b5^ho^* mouse brain at the humane end point, but still did not observe increased expression (Fig. [S3](#acn350826-sup-0001){ref-type="supplementary-material"}). We verified findings in human tissue and found comparable expression of *PDIA3* and *XBP1* splicing in white matter from controls and VWM patients (Fig. [S3](#acn350826-sup-0001){ref-type="supplementary-material"}). Microarray analyses of total RNA from postmortem white matter did not show enrichment of ATF6‐ and/or IRE1*α*‐regulated mRNAs in differentially expressed mRNAs in VWM patients compared to controls (*P* = 0.4507; Data [S4](#acn350826-sup-0005){ref-type="supplementary-material"}). These findings indicate that eIF2B mutations do not chronically activate ER stress but specifically deregulate ISR homeostasis.

Expression of the ATF4 transcriptome in 2b5^ho^ mouse brain correlates with disease development and severity {#acn350826-sec-0009}
------------------------------------------------------------------------------------------------------------

We assessed expression levels for several mRNA candidates in mouse brain between postnatal day 0 (P0) and humane end point (Fig. [2](#acn350826-fig-0002){ref-type="fig"}B). From P0 to P14 none of the tested candidates differed in the expression between WT and *2b5^ho^* brain. From P28 onwards the expression of ATF4‐regulated mRNAs changed progressively in *2b5^ho^* but not WT brain (*P* \< 0.0001; Fig. [2](#acn350826-fig-0002){ref-type="fig"}B). Maximal expression differences were measured at the humane end point.

Measuring expression of ATF4‐regulated mRNAs in brains of *2b4^ho^*, *2b5^ho^*, and *2b4^he^2b5^ho^* mice (Fig. [2](#acn350826-fig-0002){ref-type="fig"}B),[8](#acn350826-bib-0008){ref-type="ref"} we found that several correlated positively with disease severity. We did not detect ISR mRNA marker expression in brains of an unrelated neurodegenerative mouse model (Fig. [S4](#acn350826-sup-0001){ref-type="supplementary-material"}).[17](#acn350826-bib-0017){ref-type="ref"} Brain tissue from patients with multiple sclerosis (MS)[18](#acn350826-bib-0018){ref-type="ref"} or cathepsin A‐related arteriopathy with strokes and leukoencephalopathy (CARASAL)[19](#acn350826-bib-0019){ref-type="ref"} did not show consistently altered expression of ISR markers (Fig. [1](#acn350826-fig-0001){ref-type="fig"}D), indicating that ISR deregulation is not a general event in white matter disease.

ATF4 and 4E‐BP1 expression in white and gray matter astrocytes {#acn350826-sec-0010}
--------------------------------------------------------------

To identify which specific cells or brain areas display ATF4 transcriptome expression we performed immunohistochemistry for ATF4 and ATF4‐regulated 4E‐BP1[10](#acn350826-bib-0010){ref-type="ref"}, [20](#acn350826-bib-0020){ref-type="ref"} on WT and VWM mouse brain (Fig. [3](#acn350826-fig-0003){ref-type="fig"}). Antibodies for CHOP, TRIB3, and SLC3A2 did not yield specific signals. Immunohistochemistry for ATF4 showed nuclear ATF4 immunoreactivity in cerebellum, corpus callosum, and cortex in *2b5^ho^* but not WT brain (Fig. [3](#acn350826-fig-0003){ref-type="fig"}). The morphology of ATF4‐positive nuclei, based on size, degree of chromatin compaction, and presence of nucleoli, indicates that the positive cells are macroglia. 4E‐BP1 immunoreactivity was observed in white and gray matter cells of cerebellum, corpus callosum, and cortex for *2b4^ho^*, *2b5^ho^*, and *2b4^he^2b5^ho^*, but not WT mouse brain (Fig. [3](#acn350826-fig-0003){ref-type="fig"}). The latter is expected as 4E‐BP1 is not expressed in WT brain[21](#acn350826-bib-0021){ref-type="ref"}. Cells were already 4E‐BP1‐positive in a 1‐month‐old *2b5^ho^* mouse, in line with qPCR findings (Fig. [2](#acn350826-fig-0002){ref-type="fig"}B, Fig. [S5](#acn350826-sup-0001){ref-type="supplementary-material"}). The morphology of the 4E‐BP1‐positive cells corresponded to white and gray matter astrocytes, including Bergmann glia. Double stainings with antibodies against ATF4 or 4E‐BP1 and astrocyte marker GFAP revealed ATF4‐GFAP and 4E‐BP1‐GFAP double‐positive cells in brain sections of *2b4^he^2b5^ho^* or *2b5^ho^* but not WT mice (Fig. [4](#acn350826-fig-0004){ref-type="fig"}). All GFAP‐positive cells were ATF4‐positive in *2b4^he^2b5^ho^* brain sections. No 4E‐BP1‐positive cells with the morphology of oligodendrocytes were detected in *2b4^ho^*, *2b5^ho^*, and *2b4^he^2b5^ho^* brain, even at humane end point (Figs. [3](#acn350826-fig-0003){ref-type="fig"} and [4](#acn350826-fig-0004){ref-type="fig"}). Double stainings with antibodies against 4E‐BP1 and Olig2, marker for oligodendrocytes[22](#acn350826-bib-0022){ref-type="ref"}, did not show any double‐positive cells in *2b5^ho^* mouse brain (Fig. [4](#acn350826-fig-0004){ref-type="fig"}). Double stainings with antibodies against Olig2 and ATF4 to investigate ATF4 expression in oligodendrocytes are infeasible, as the Olig2 signal is much higher than the ATF4 signal and both signals localize in the nuclei. 4E‐BP1 signal localizes in the cytoplasm, favoring Olig2‐4E‐BP1 co‐staining.

![White and gray matter astrocytes in VWM mice and VWM patients are immunoreactive for ATF4‐regulated 4E‐BP1. (A) ATF4 immunoreactive nuclei (brown) are detected in white and gray matter macroglia of VWM mice. Two sections from brain tissue from 4‐month‐old WT and *2b5^ho^* mice (*n* = 2) were stained with antibodies against ATF4. Findings in cerebellum, corpus callosum, and cortex are indicated. Staining for ATF4 on human brain sections was not successful. (B) White and gray matter astrocytes in VWM mouse and VWM human brain in show 4E‐BP1 immunoreactivity (brown). Two brain sections from 4‐month‐old mice (WT, *2b5^ho^*, and *2b4^he^2b5^ho^*), human control (C1) or patients (VWM 1 and VWM 2) were stained with antibodies against 4E‐BP1. Details on human brain tissue are listed in Data [S5](#acn350826-sup-0006){ref-type="supplementary-material"}. Findings in cerebellum, corpus callosum (mouse) or frontal white matter (WM, human) and cortex are shown. Purple stain indicates nuclei. White bar, 0.05 mm.](ACN3-6-1407-g003){#acn350826-fig-0003}

![Costaining for ATF4 or 4E‐BP1 with GFAP or OLIG2 demonstrate double positive cells of astrocyte but not oligodendrocyte lineage in VWM mice. ATF4‐GFAP costaining was only successful on sections from *2b4^he^2b5^ho^* mice (4‐month‐old). Arrows indicate nuclei of double positive Bergmann glia. Shown are representative sections from a total of four sections (*n* = 2 animals per group). 4E‐BP1 + GFAP staining of astrocytes in cortex is at 2‐month‐old age. 4E‐BP1 + GFAP and 4E‐BP1 + OLIG2 double staining of cerebellar white matter (cb WM) is at an age of 12 months (HEP, *2b5^ho^*). Double positive astrocytes were prominent, whereas oligodendrocytes were not detected, even at HEP. Shown are representative sections from a total of 3--4 sections (*n* = 2 animals per group).](ACN3-6-1407-g004){#acn350826-fig-0004}

4E‐BP1‐positive cells with the morphology of astrocytes were also detected in the frontal white matter, cerebellum, and cortex of brain tissue from VWM patients (Fig. [3](#acn350826-fig-0003){ref-type="fig"}); 4E‐BP1‐positive cells with the morphology of oligodendrocytes or neurons were not observed. 4E‐BP1‐positive astrocytes, oligodendrocytes or neurons were not observed in brains from one MS and two CARASAL patients (Fig. [S6](#acn350826-sup-0001){ref-type="supplementary-material"}). Staining with ATF4 antibody was unsuccessful in human brain.

ISRIB injections differentially normalize clinical signs of VWM mice {#acn350826-sec-0011}
--------------------------------------------------------------------

We postulate that the expression of ATF4 transcriptome in astrocytes underlies their dysfunction. To reduce expression of the ATF4 transcriptome we targeted the ISR with ISRIB[9](#acn350826-bib-0009){ref-type="ref"}, [23](#acn350826-bib-0023){ref-type="ref"}, [24](#acn350826-bib-0024){ref-type="ref"}, [25](#acn350826-bib-0025){ref-type="ref"}, [26](#acn350826-bib-0026){ref-type="ref"}. We used *2b5^ho^* and *2b4^ho^2b5^he^* genotypes to determine ISRIB's effects on a moderate and severe variant of VWM and on both mutations.

ISRIB increased VWM but not WT mouse body weight compared to placebo‐injected controls (Fig. [5](#acn350826-fig-0005){ref-type="fig"}A and Fig. [S7](#acn350826-sup-0001){ref-type="supplementary-material"}). Weight gain was fastest and highest in *2b4^ho^2b5^he^* mice. Neurological deterioration as assessed by neuroscores[27](#acn350826-bib-0027){ref-type="ref"} was observed in placebo‐treated *2b5^ho^* and *2b4^ho^2b5^he^* mice after 18--20 or 11--12 weeks of injections (Fig. [5](#acn350826-fig-0005){ref-type="fig"}B). ISRIB‐treated *2b5^ho^* mice showed signs of mild neurological deterioration toward the end, whereas ISRIB‐treated *2b4^ho^2b5^he^* mice did not show neurological signs for the duration of the experiment (Fig. [5](#acn350826-fig-0005){ref-type="fig"}B). Motor tests at the end of the experiment revealed that ISRIB improved performance of VWM mice in Balance Beam tests (Fig. [5](#acn350826-fig-0005){ref-type="fig"}C). All static and dynamic gait parameters in the catwalk were more affected in placebo‐treated *2b4^ho^2b5^he^* mice than placebo‐treated *2b5^ho^* mice (Fig. [5](#acn350826-fig-0005){ref-type="fig"}D, Fig. [S8](#acn350826-sup-0001){ref-type="supplementary-material"}). ISRIB normalized all gait parameters in *2b4^ho^2b5^he^* mice (Fig. [5](#acn350826-fig-0005){ref-type="fig"}D; Data [S6](#acn350826-sup-0007){ref-type="supplementary-material"}). ISRIB effects on gait parameters were less consistent and less pronounced in *2b5^ho^* than in *2b4^ho^2b5^he^* mice (Fig. [5](#acn350826-fig-0005){ref-type="fig"}D, Fig. [S8](#acn350826-sup-0001){ref-type="supplementary-material"}). ISRIB did not affect any parameters in WT mice (Fig. [5](#acn350826-fig-0005){ref-type="fig"}D, Fig. [S8](#acn350826-sup-0001){ref-type="supplementary-material"}).

![ISRIB ameliorates clinical signs in two VWM mouse models, most effectively in *2b4^ho^2b5^he^* mice. Mice were injected daily with vehicle or 1 mg/kg ISRIB from an age of 6--8 weeks onwards. (A--D) Graphs show phenotypic measures of placebo‐ and ISRIB‐treated WT (*n* = 6 per condition) and VWM mice (*2b5^ho^* and *2b4^ho^2b5^he^ n* = 14 per condition or as indicated): average body weight of WT and VWM mice (A), average neuroscore in VWM mice (B), average number of slips on balance beam (*2b5^ho^ n* = 11 for placebo, *n* = 13 for ISRIB and *2b4^ho^2b5^he^ n* = 10 for placebo and *n* = 13 for ISRIB, (C), average measures of selected CatWalk parameters (*2b5^ho^ n* = 9 for placebo, *n* = 13 for ISRIB and *2b4^ho^2b5^he^ n* = 12 for placebo and *n* = 14 for ISRIB, (D). Error bars indicate SD (graph b), SEM (graphs in c, d), or are left out (graph in a) to allow visualization of the mean values (SEM is shown in Data [S6](#acn350826-sup-0007){ref-type="supplementary-material"}). Raw data of all CatWalk parameters are given in Data [S6](#acn350826-sup-0007){ref-type="supplementary-material"}. Statistical analysis investigating the ISRIB differences in WT, *2b5^ho^* and *2b4^ho^2b5^he^* was performed with a two‐way ANOVA with Tukey's correction (Data [S6](#acn350826-sup-0007){ref-type="supplementary-material"}). \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001.](ACN3-6-1407-g005){#acn350826-fig-0005}

ISRIB impacts expression of ISR mRNA markers and improves histopathology {#acn350826-sec-0012}
------------------------------------------------------------------------

ISRIB reduced expression of *Atf4* and ATF4‐regulated mRNAs in the brains of VWM mice, most consistently in *2b4^ho^2b5^he^* mice (Fig. [6](#acn350826-fig-0006){ref-type="fig"}A). ISRIB did not affect eIF2*α* phosphorylation levels in *2b5^ho^* and *2b4^ho^2b5^he^* mice, despite reduced *Gadd34* mRNA levels (Fig. [6](#acn350826-fig-0006){ref-type="fig"}A). ISRIB reduced *Eif4ebp1* mRNA and 4E‐BP1 protein expression in ISRIB‐injected *2b4^ho^2b5^he^* mice (Fig. [6](#acn350826-fig-0006){ref-type="fig"}A), which was not observed in ISRIB‐injected WT or *2b5^ho^* animals.

![ISRIB modulates aberrant expression of ATF4‐regulated mRNAs and ameliorates neuropathological astrocyte markers in VWM mouse cerebellum and corpus callosum. (A) Cerebellar expression of ATF4‐regulated mRNAs, eIF2*α* phosphorylation, and 4E‐BP1 protein expression were measured in placebo‐ and ISRIB‐treated WT and VWM mice (*n* = 6 per group). Graphs show average ± SD. Two‐way ANOVA with Tukey's correction was performed for each target. (B) Brain sections from placebo‐ and ISRIB‐treated *2b5^ho^* and *2b4^ho^2b5^he^* mice (*n* = 2 per group, 2 sections per animal) were stained with antibodies against S100*β*. Thickness of Bergmann glia (BG) processes is reduced by ISRIB in *2b4^ho^2b5^he^* mice; white bar, 0.05 mm. (C) Counts of mislocalized and normally localized S100*β*‐positive Bergmann glia shows that ISRIB does not fully normalize Bergmann glia location in VWM mice. Differences in the ratio of mislocalized:normal localized Bergmann glia were statistically assessed by two‐way ANOVA with Tukey's correction. (D and E) ISRIB reduces number of nestin‐GFAP double positive astrocytes in *2b4^ho^2b5^he^* mice (2 sections per rostrum and splenium of the corpus callosum for 2 animals per group). The average number of nestin‐GFAP double positive astrocytes in four untreated WT animals was included as reference (indicated as dotted line in the graph). Statistical differences were determined with one‐way ANOVA using Tukey's correction. White bar in immunofluorescence, 0.05 mm. (F) ISRIB restored levels of mature myelin mRNA markers in *2b4^ho^2b5^he^* mice. Graphs show average ± SD (*Akt* + *Gapdh,* qPCR reference). Two‐way ANOVA was performed for each target using Tukey's correction. (G) ISRIB restores immunoreactivity for mature myelin protein MOG in white matter structures in *2b4^ho^2b5^he^* mice. Shown are representative sections from a total of four sections (*n* = 2 mice per group). Black bar, 0.05 mm. For all graphs, \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \< 0.001, \*\*\*\**P* \< 0.0001. Statistical test outcomes are in Data [S6](#acn350826-sup-0007){ref-type="supplementary-material"}.](ACN3-6-1407-g006){#acn350826-fig-0006}

Bergmann glia localization in VWM mouse brain was improved by ISRIB more clearly in *2b4^ho^2b5^he^* than in *2b5^ho^* mice (Fig. [6](#acn350826-fig-0006){ref-type="fig"}B). Bergmann glia were localized closer to the Purkinje cell bodies with ISRIB treatment, but did not reach or maintain their normal position completely (Fig. [6](#acn350826-fig-0006){ref-type="fig"}B), causing quantification of the changes in proportion of mislocalized Bergmann glia not reaching significance (Fig. [6](#acn350826-fig-0006){ref-type="fig"}C).

The number of nestin and GFAP double‐positive immature astrocytes normalized in ISRIB‐injected *2b4^ho^2b5^he^* mice and was reduced in *2b5^ho^* mice, although statistical significance was not reached for the latter (Fig. [6](#acn350826-fig-0006){ref-type="fig"}D and E). ISRIB effects on myelin in VWM mice were evident in mature myelin *Mbp* and *Mog* mRNA levels, MBP protein levels and MOG immunohistochemistry in *2b4^ho^2b5^he^* mice only (Fig. [6](#acn350826-fig-0006){ref-type="fig"}F and G, Fig. [S9](#acn350826-sup-0001){ref-type="supplementary-material"}). *Olig2* mRNA levels were similar in all groups (Fig. [S9](#acn350826-sup-0001){ref-type="supplementary-material"}). No ISRIB effects on histology were observed in WT mice (not shown).

ISRIB concentrations in venous blood drawn after 2 weeks of injections were similar in *2b5^ho^* and *2b4^ho^2b5^he^* mice albeit lower than in WT mice (Fig. [7](#acn350826-fig-0007){ref-type="fig"}A). ISRIB's concentrations in postmortem blood and brain samples were similar in all three genotypes and are well above ISRIB's reported half maximal effective concentration (EC50) of 0.75nM (corresponding to 0.35ng/ml; Fig. [7](#acn350826-fig-0007){ref-type="fig"}B)[28](#acn350826-bib-0028){ref-type="ref"}, indicating that ISRIB's differential effect on phenotypic measures in *2b5^ho^* versus *2b4^ho^2b5^he^* mice cannot be attributed to differences in ISRIB bioavailability in brain. ISRIB's therapeutic effect may be influenced by the specific mutation. A recent study shows that ISRIB's EC50 is decreased by the Arg483Trp mutation in human eIF2Bδ.[28](#acn350826-bib-0028){ref-type="ref"} We measured ISRIB's effect on protein synthesis rates in cultured astrocytes from WT, *2b5^ho^* and *2b4^ho^2b5^he^* mice undergoing a UPR (Fig. [7](#acn350826-fig-0007){ref-type="fig"}C). ISRIB appeared more effective in *2b4^ho^2b5^he^* than in WT and *2b5^ho^* astrocytes (Fig. [7](#acn350826-fig-0007){ref-type="fig"}C), although the number of measurements is limited.[29](#acn350826-bib-0029){ref-type="ref"} We also found that protein synthesis in transfected *2b4^ho^2b5^he^* astrocytes was more sensitive to low concentrations of ISRIB than transfected WT astrocytes (Fig. [7](#acn350826-fig-0007){ref-type="fig"}D; 4--6 measurements). Increased ISRIB sensitivity was not observed in *2b5^ho^* astrocytes (Fig. [7](#acn350826-fig-0007){ref-type="fig"}D).

![ISRIB's efficacy in VWM is influenced by the identity of eIF2B mutation. (A) ISRIB concentrations were determined in venous blood samples obtained from WT (*n* = 6 per group) and VWM mice (*2b5^ho^* and *2b4^ho^2b5^he^ n* = 14 per group) after 14 days of daily ISRIB injections (24 h after the latest injection); data obtained from placebo‐treated animals were below detection and were omitted from the graph. Statistical differences among genotypes were determined with one‐way ANOVA followed by Tukey's correction. (B) ISRIB concentrations were determined in postmortem blood and olfactory bulb tissue from WT (*n* = 2 per group) and VWM mice (*2b5^ho^* and *2b4^ho^2b5^he^ n* = 9 and *n* = 8 per group). Statistical differences were determined with Two‐way ANOVA (tissue and genotype as factors) with Tukey's correction. (C) ISRIB restored protein synthesis rates in primary cultures of adult mouse astrocytes undergoing UPR, most effectively in cells from *2b4^ho^2b5^he^* mice. TG effects were not statistically significant as before[29](#acn350826-bib-0029){ref-type="ref"}. Statistical differences in test conditions (DMSO vs. TG vs. TG + ISRIB within WT, *2b5^ho^*, and *2b4^ho^2b5^he^* adult mouse astrocytes were determined with two‐way ANOVA with Tukey's correction (*n* = 2). (D) ISRIB enhanced expression of *Gapdh*‐driven firefly luciferase reporter in *2b4^ho^2b5^he^* astrocytes at lower concentrations than in WT or *2b5^ho^* astrocytes (*P* = 0.0026). WT1 and WT2 indicate different isolation dates. Cells were exposed to 300 nmol/L thapsigargin for 16 h with increasing concentrations of ISRIB. Areas under curve (AUC) were calculated for each cell isolate per transfection experiment after correcting for differences between experiments but not between test conditions within experiments (genotype, treatments). Statistical differences between ISRIB sensitivity in WT1, WT2, *2b5^ho^*, and *2b4^ho^2b5^he^* adult mouse astrocytes were determined with one‐way ANOVA with Sidak's correction using AUC values. For all panels, \**P* \< 0.05, \*\**P* \< 0.01. Statistical test outcomes are in Data [S6](#acn350826-sup-0007){ref-type="supplementary-material"}. Graphs show mean ± SD (A--C) or mean ± SEM (D).](ACN3-6-1407-g007){#acn350826-fig-0007}

Discussion {#acn350826-sec-0013}
==========

One study objective was to contribute to unraveling VWM pathophysiology, a leukodystrophy characterized by primary astrocyte pathology.[8](#acn350826-bib-0008){ref-type="ref"} With VWM mice we study the chronic disease; acute deteriorations have not been modeled yet.[29](#acn350826-bib-0029){ref-type="ref"} We demonstrate increased expression of ATF4‐regulated transcriptome in *2b5^ho^* brain from before disease onset. Its expression level correlates with disease development and severity. Strikingly, this ATF4‐regulated transcriptome is expressed selectively in astrocytes and not in other cell types in VWM mouse and patient brain; it is specific for VWM and not a general response to white matter disease.

Our study disproves the concept that the UPR is activated in VWM[30](#acn350826-bib-0030){ref-type="ref"}. Reduced phosphorylated eIF2*α* in *2b5^ho^* mouse and VWM patient brains argues against cell stress as initiating event; reduced activity of mutant eIF2B by itself can explain the increased expression of ATF4 and its transcriptome, including *Gadd34*.[3](#acn350826-bib-0003){ref-type="ref"} Increased GADD34 can explain the decrease in phosphorylated eIF2*α*. That eIF2*α* phosphorylation is reduced below baseline indicates a constitutively activated feedback mechanism. Considering that ATF4 is still expressed, reduced eIF2*α* phosphorylation is apparently unable to fully compensate reduced eIF2B activity. With complete compensation, ATF4 levels would have been similar in WT and VWM brain. Together our findings reveal a constitutively and increasingly deregulated ISR homeostasis in VWM. Recently, others have reported normal eIF2*α* phosphorylation in *2b5^ho^* mice[31](#acn350826-bib-0031){ref-type="ref"}, which may be ascribed to technical variation, as the phosphorylated eIF2*α* signal is fairly low.[31](#acn350826-bib-0031){ref-type="ref"}

We previously demonstrated that guanabenz improves white matter and astrocyte pathology in *2b5^ho^* mice.[32](#acn350826-bib-0032){ref-type="ref"} Guanabenz is an *α*2‐adrenergic receptor agonist that also targets the ISR and reduces expression of ATF4‐regulated transcriptome[27](#acn350826-bib-0027){ref-type="ref"}. We now demonstrate that ISRIB, which activates eIF2B and thereby reduces expression of the ATF4‐regulated transcriptome, improves white matter and astrocyte pathology and ameliorates the clinical disease in VWM mice, arguing against the *α*2‐adrenergic receptor as mechanism through which guanabenz had its impact on VWM.

We conclude that reduced activity of mutant eIF2B initiates the disease in VWM. It increases expression of ATF4 and ATF4‐regulated transcriptome, which is moderated through the GADD34 feedback loop, decreasing eIF2*α* phosphorylation to even below control level. The latter is insufficient to normalize eIF2B activity, resulting in constitutive and increasing activation of the ATF4 transcriptome, causing disease.

In line with a previous study[23](#acn350826-bib-0023){ref-type="ref"}, ISRIB did not affect eIF2*α* phosphorylation in VWM mice. A rise in eIF2 phosphorylation would have been expected, as ISRIB reduced *Gadd34* mRNA levels. Possibly, the ISRIB‐induced reduction in GADD34 protein level was not sufficient to achieve this. The ATF4 expression was not completely normalized either by ISRIB, as exemplified by 4E‐BP1 protein expression still being detected in brain tissue of ISRIB‐treated VWM mice (Fig. [6](#acn350826-fig-0006){ref-type="fig"}). Both findings suggest that ISRIB treatment does not fully normalize eIF2B activity, but leads to a better compensated system that still in part depends on reduced eIF2*α* phosphorylation.

ISRIB stabilizes the eIF2B complex formation through interaction with the eIF2Bδ:eIF2B*β* interface[33](#acn350826-bib-0033){ref-type="ref"}, [34](#acn350826-bib-0034){ref-type="ref"}. Its effect may be influenced by the specific VWM mutation. The eIF2Bδ Arg483Trp mutation is close to the ISRIB‐binding site[33](#acn350826-bib-0033){ref-type="ref"} and may enhance ISRIB binding. The eIF2Bδ Arg483Trp mutation also interferes with eIF2B complex stability[3](#acn350826-bib-0003){ref-type="ref"}, whereas the eIF2Bε Arg195His mutation does not and possibly reduces eIF2B activity through another mechanism.[35](#acn350826-bib-0035){ref-type="ref"} ISRIB may preferentially impact eIF2B with complex‐destabilizing mutations.

The question how ISR deregulation causes pathology remains difficult to answer. Our overrepresentation analyses on regulated mRNAs in *2b5^ho^* mouse brain highlight increased functions of amino acid transport and biosynthesis of serine, glycine and cysteine. Several related genes are regulated by ATF4.[10](#acn350826-bib-0010){ref-type="ref"} Increased serine and glycine levels have been reported in cerebrospinal fluid of VWM patients[36](#acn350826-bib-0036){ref-type="ref"}, indicating that the identified functions are indeed likely deregulated. Interestingly, serine, glycine, and cysteine are used with glutamate for synthesis of the antioxidant glutathione (GSH).[37](#acn350826-bib-0037){ref-type="ref"} The ATF4‐regulated transcription is known to aid in counteracting reactive oxygen species (ROS).[38](#acn350826-bib-0038){ref-type="ref"} ROS typically induce eIF2*α* phosphorylation.[39](#acn350826-bib-0039){ref-type="ref"} In brains of VWM mice and VWM patients, eIF2*α* phosphorylation is low, suggesting that ROS levels are not enhanced. The ATF4‐induced increased synthesis and secretion of GSH by astrocytes may thus induce reductive shifts in the steady‐state redox potential[40](#acn350826-bib-0040){ref-type="ref"}, which may inhibit maturation of oligodendrocyte precursor cells.[41](#acn350826-bib-0041){ref-type="ref"} Strikingly, an astrocyte‐dependent impairment of oligodendrocyte maturation is a central feature of VWM.[2](#acn350826-bib-0002){ref-type="ref"}, [8](#acn350826-bib-0008){ref-type="ref"} All data combined suggest that the defect in oligodendrocyte maturation may be due to a reductive shift in redox potential in mutant astrocytes induced by ISR‐deregulation (Fig. [S10](#acn350826-sup-0001){ref-type="supplementary-material"}).

We achieved our second objective by confirming that ISR modulation can improve VWM. ISRIB targets eIF2B from various species, ranging from mice to humans[9](#acn350826-bib-0009){ref-type="ref"}, [25](#acn350826-bib-0025){ref-type="ref"}, [33](#acn350826-bib-0033){ref-type="ref"}, indicating that ISRIB is probably also efficacious in VWM patients. ISRIB's effect may be influenced by the specific eIF2B mutations and it may not be equally effective in all patients. Testing ISRIB on patient cells before prescription may be required. Additionally, ISRIB has low solubility and its bioavailability in humans needs optimization. Recently, a soluble ISRIB derivative (2BAct) was successful in preventing VWM clinical signs and neuropathology in a *2b5^ho^* mouse model.[31](#acn350826-bib-0031){ref-type="ref"}

We have demonstrated that ISR derangement is central in VWM pathogenesis and that the ISR is a viable drug target for VWM. The role of ISR regulation in health and disease is currently at the center of attention in aging and various neurodegenerative diseases, including Alzheimer disease, Parkinson disease and ALS.[42](#acn350826-bib-0042){ref-type="ref"}, [43](#acn350826-bib-0043){ref-type="ref"} This study reveals that modulation of ISR deregulation ameliorates neurological dysfunction in VWM mice without affecting general health, indicating the potential of ISRIB for patients with VWM and other conditions characterized by abnormal ISR activation.
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